Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 27.33
- Piotroski Score 5.00
- Grade Buy
- Symbol (CORT)
- Company Corcept Therapeutics Incorporated
- Price $45.74
- Changes Percentage (2.42%)
- Change $1.08
- Day Low $44.66
- Day High $45.94
- Year High $47.71
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/30/2024
- Fiscal Year End N/A
- Average Stock Price Target $60.50
- High Stock Price Target $78.00
- Low Stock Price Target $38.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $1.05
- Trailing P/E Ratio 31.72
- Forward P/E Ratio 31.72
- P/E Growth 31.72
- Net Income $106.14 M
Income Statement
Quarterly
Annual
Latest News of CORT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Jets security had to escort Robert Saleh out of team building after firing: reports
New York Jets head coach Robert Saleh was fired by owner Woody Johnson. Defensive coordinator Jeff Ulbrich is the interim head coach. Saleh plans to interview for defensive coordinator positions. Aaro...
By Fox News | 18 hours ago -
Corcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Is Going Strong: Is the Market Following Fundamentals?
Corcept Therapeutics' stock has surged 52% in the past three months. Analyzing its ROE of 21%, which indicates efficient capital utilization, the company's growth potential is promising despite low ne...
By Yahoo! Finance | 2 days ago -
Corteva Inc. (CTVA): One of the Best Stocks to Buy According to Larry Robbins
Larry Robbins' hedge fund, Glenview Capital Management, focuses on healthcare and investment trends, like Obamacare. They saw success in 2013 and continue to invest strategically. Corteva Inc. (NYSE:C...
By Yahoo! Finance | 2 days ago
